Mediscience's Biopsy Pill possible industry standard, confirmed by independent assessment

By Lisa Kerner

Erie, Pa., May 24 - Mediscience said its Biopsy Pill demonstrates promise in providing a real-time non-invasive, preliminary means of detecting in vivo pre-cancerous and cancerous tissues in the upper digestive tract, according to a company news release.

An independent assessment of the photonics-based ingestible pill by Syracuse University compared similar competitor technology platforms combining remote operations, in vivo imaging chemical analysis (MEMS, MOEMS, Given/Olympus, Smartpill) and the use of photonics data (MTC/Infotronics).

The report indicates that the Biopsy Pill has the potential to become a market leader or the industry standard, with no obvious intellectual property barriers to commercialization.

"Our agreement with equity partner Infotonics to jointly develop the Compact Photonic Explorer, or pill camera, for medical applications is a synergistic and strategic fit leveraging the Center's unique nano-technology capabilities and resources to provide Mediscience, present and future associates with an exceptional state of the art competitive advantage," chief executive officer Peter Katevatis said in the release.

The Infotonics Technology Center Inc. is a not-for-profit consortium which operates New York State's Center of Excellence in Photonics and Microsystems. Participants include Corning, Inc., Eastman Kodak Co. and Xerox Corp.

Mediscience, located in Cherry Hill, N.J., designs, develops and commercializes medical devices that detect cancer and physiological change using frequencies of light.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.